Compare Progressive Corp (PGR) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Progressive Corp vs Recursion Pharmaceuticals Inc — how do they compare? Progressive Corp trades at $218.73 (market cap $124.28B), while Recursion Pharmaceuticals Inc trades at $3.99 (market cap $2.31B). The key difference: Progressive Corp is far larger — about 53.8× Recursion Pharmaceuticals Inc's market cap, and Progressive Corp pays a 0.19% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Progressive Corp for 81 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| PGR | RXRX | |
|---|---|---|
Market Cap | $124.28B | $2.31B |
Volume | 2,551,191 | 40,478,768 |
Sector | Financials | Health |
52-Week High | $242.16 | $6.79 |
52-Week Low | $190.40 | $2.84 |
Typical Hold Time | 81 Days | 22 Days |
Enterprise Value | $132.48B | $1.83B |
Dividend Yield | 0.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PGR trades at $218.73, up 3.15% today, with a bullish technical signal from moving averages and strong fundamentals including a 12.85% net income margin and 34.94% ROE. Revenue grew from $49.6B in 2022 to $87.6B in 2025, with net income surging to $11.3B. The company recently announced a $0.10 dividend payable in October 2026, and Q2 2026 earnings beat expectations.
The outlook is positive given robust earnings growth and analyst consensus price target of $222.23, though risks include intensifying competition in personal auto insurance and potential market volatility. Institutional interest remains strong with recent position increases by funds like QRG Capital Management.
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Progressive Corp
Progressive underwrites private and commercial auto insurance and specialty lines
Read more on PGR →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
